Roche was forced to revise its forecasts for biosimilar competition last year, but even an upward revision of CHF1bn fell short as biosimilar sponsors stole a march in the US at a level that caught the originator by surprise.
Roche has expressed surprise at the level of penetration last year in the US for long-heralded biosimilar versions of Avastin (bevacizumab), MabThera/Rituxan (rituximab) and Herceptin (trastuzumab), as full-year financial figures revealed the global impact of biosimilars was higher even than the originator’s recently revised estimates.
In 2020, biosimilar competition to the three oncology blockbusters led relative sales in the US, Europe and Japan to plunge...
The International Generic and Biosimilar medicines Association has set out three priority areas that it says should be considered by G7 leaders at the current summit in Alberta, Canada, as part of efforts towards ensuring access to health.
Outlook Therapeutics has started to conquer European markets with its ophthalmic version of bevacizumab. Meanwhile, across the pond in the US, it awaits the FDA’s decision, again.
Xbrane Biopharma is partnering with India’s OneSource Specialty Pharma to manufacture its biosimilars, including its much-delayed ranibizumab product Ximluci. The move follows a SEK240m funding round and strategic refocus on commercialization after divesting key R&D assets to Alvotech.
Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.
